ATRA
Atara Biotherapeutics, Inc.
There isn't enough reported data to score ATRA yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
ATRA Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Strong |
ATRA's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ATRA PE Valuation
ATRA has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ATRA Forward outlook
There aren't enough analyst estimates for ATRA to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ATRA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$25.53 | +$44.22 |
| Q2 2024 | -$39.10 | +$34.65 |
| Q1 2024 | -$53.00 | -$0.75 |
| Q4 2023 | -$65.25 | -$9.25 |
| Q3 2023 | -$69.75 | -$8.00 |
| Q2 2023 | -$73.75 | -$10.00 |
| Q1 2023 | -$52.25 | +$38.75 |
| Q4 2022 | -$56.00 | +$34.75 |
LLY has the stronger earnings trend. Trailing diluted EPS is down 106% for ATRA versus LLY up 51%.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.83 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
ATRA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.2M | -65% |
| Q2 2026 | $630K | -96% |
| Q1 2026 | $516K | -99% |
| Q4 2025 | $1.6M | -95% |
| Q3 2025 | $3.5M | -91% |
| Q2 2025 | $17.6M | -39% |
| Q1 2025 | $98.1M | +259% |
| Q4 2024 | $32.8M | +670% |
ATRA's revenue has slid since its 2025 peak: $1M last quarter, down 65% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -243% | -139 points |
| Q2 2026 | -749% | -767 points |
| Q1 2026 | -653% | -692 points |
| Q4 2025 | -161% | -123 points |
| Q3 2025 | -104% | -49 points |
| Q2 2025 | 18% | +82 points |
| Q1 2025 | 40% | +154 points |
| Q4 2024 | -37% | +1373 points |
ATRA's operating margin was −243% last quarter, down 139 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ATRA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ATRA on profitability, with a higher operating margin.
ATRA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$879K | +$8.9M |
| Q2 2026 | -$3.3M | +$4M |
| Q1 2026 | -$3.1M | +$25.1M |
| Q4 2025 | -$5.7M | +$18.9M |
| Q3 2025 | -$9.8M | -$5.8M |
| Q2 2025 | -$7.3M | +$3.4M |
| Q1 2025 | -$28.1M | +$1.6M |
| Q4 2024 | -$24.6M | +$25.9M |
ATRA has burned cash in almost every quarter: −$13M over the past year, against −$70M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ATRA on cash generation, producing positive trailing cash flow while its opponent burns cash.
ATRA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.9% | +293K shares |
| 1 year | +25% | +3M shares |
| 3 years | +269% | +11.2M shares |
| 5 years | +319% | +11.7M shares |
| Available history | +647% | +13.3M shares |
ATRA has 15M diluted shares, up 25% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ATRA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ATRA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | -0.2x | Net Cash |
| Q3 2025 | -0.2x | Net Cash |
| Q2 2025 | -1.4x | Net Cash |
ATRA has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ATRA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.3 | Neutral |
| Stochastic | 12.7 | Oversold |
ATRA's weekly RSI is 44 (neutral) and its Stochastic is 13 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ATRA PE vs Healthcare Sector
ATRA has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ATRA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.67 | 8.5% below |
| 20 week MA | $8.98 | 12% below |
| 50 week MA | $8.74 | 9.3% below |
| 100 week MA | $9.48 | 16% below |
| 200 week MA | $21.2 | 63% below |
ATRA is in a downtrend: it's below all five of its weekly moving averages, and 63% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ATRA on trend strength, trading above more of its moving averages.
ATRA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $412.8 | $554.5 | +34% |
| 2021 | $554.5 | $432.8 | -22% |
| 2022 | $432.8 | $74.8 | -83% |
| 2023 | $74.8 | $12.8 | -83% |
| 2024 | $12.8 | $12.2 | -5.2% |
| 2025 | $12.2 | $17.3 | +42% |
| 2026 YTD | $17.3 | $7.93 | -54% |
ATRA has finished lower in four of the last six years. It's down 54% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ATRA on returns for 2026, with the stronger performance.